Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review.
Adjuvants, Immunologic
/ administration & dosage
Administration, Intravesical
Aftercare
/ standards
Antineoplastic Agents
/ administration & dosage
BCG Vaccine
/ administration & dosage
Carcinoma, Transitional Cell
/ diagnosis
Chemotherapy, Adjuvant
/ methods
Cystectomy
/ standards
Cystoscopy
/ standards
Guideline Adherence
/ statistics & numerical data
Humans
Medical Oncology
/ standards
Muscle, Smooth
/ diagnostic imaging
Neoplasm Invasiveness
Practice Guidelines as Topic
Urinary Bladder
/ diagnostic imaging
Urinary Bladder Neoplasms
/ diagnosis
Urology
/ standards
Compliance
Guideline
Nonmuscle-invasive bladder carcinoma
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
05
02
2020
revised:
02
05
2020
accepted:
13
06
2020
pubmed:
14
7
2020
medline:
29
6
2021
entrez:
14
7
2020
Statut:
ppublish
Résumé
This systematic review assessed compliance to guidelines for the management of nonmuscle-invasive bladder carcinoma (NMIBC). The PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched in November 2019 in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Fifteen studies incorporating a collective total of 10,575 NMIBC patients were eligible for inclusion in this systematic review. We found that the rates of compliance were 53.0% with a single immediate intravesical instillation in patients with presumed low or intermediate risk, 37.1% with intravesical bacillus Calmette-Guerin or chemotherapy in those with intermediate risk, 43.4% with performance of a second transurethral resection in high-risk patients, 32.5% with administration of adjuvant intravesical bacillus Calmette-Guerin in high-risk patients, 36.1% with radical cystectomy in highest-risk patients, and 82.2% with cystoscopy for follow-up. Compliance with NMIBC guidelines remains low. Better guideline education and understanding holds the key to achieving high compliance. Strategies to improve guideline compliance at the physician level are urgently required.
Identifiants
pubmed: 32654948
pii: S1078-1439(20)30281-7
doi: 10.1016/j.urolonc.2020.06.013
pii:
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antineoplastic Agents
0
BCG Vaccine
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
774-782Informations de copyright
Copyright © 2020. Published by Elsevier Inc.